MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Alzheimers & Dementia
NervGen Pharma Corp. (NGENF
Organization & Developments: NervGen Pharma
Parents
NervGen Pharma Corp. (NGENF
Children
*Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various indications. :ead product is NVG-291 which we are planning to develop for multiple sclerosis, Alzheimer’s disease, and spinal cord injury.
*NervGen is dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.
*NervGen’s focus is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, Organization & Developments: NervGen Pharma
*NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration, remyelination and plasticity.
2024: NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025
2025: NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
2025: NervGen Pharma: Risky, Yet Promising With Big Upside
Jumps
Finance & Acquisition: NervGen Pharma
Key People: NervGen Pharma